Patent Application
20150037251
The present invention relates to mammalian homologues of the drosophila Fwe (Flower) protein and its encoding nucleic acids. The invention provides means and methods, particularly antibodies and inhibitory nucleic acids useful for diagnostics, prevention and treatment of cancer.
Tumor formation is preceded by clonal expansion of pretumoral, mutant cells. Clones of pretumoral cells are often invisible to the naked eye, due to absence of morphological alterations in the tissue. It was proposed that such clones facilitate their own expansion by interacting with the surrounding normal cells (Moreno (2008), Nat Rev Cancer 8, 141-147). Such interaction can be based on the relative cellular fitness status of the cell: cells of higher fitness are selected and persist in the tissue at the expense of less fit ones.
Recent studies demonstrate that, in Drosophila, the mechanism through which cells of lower fitness are recognized and eliminated from a tissue depends on the function of an extracellular molecular code, called “The Flower Code” (Rhiner et al. (2010) Dev. Cell 18, 1-14). This code is based on three isoforms of the cell membrane protein Flower (Fwe): Few(ubi), Few(Lose-A) and Few(Lose-B). Basal levels of Fweubi are constantly produced in the Drosophila wing imaginal disc, but when cells of lower relative fitness (but which are viable on their own) appear, they are recognized due to the up-regulation of the few(Lose) isoforms, which eventually leads to caspase 3 activation in such “loser” cells.
Agents that regulate cell competition in mammals have not been described in the prior art. The mammalian homologues of Drosophila fwe (dfwe) have not been studied so far and their function is not known. The single mouse C9orf7 gene has been isolated and described (Yao et al. (2008) Cell 138, 947-960), but its role in cell competition has not been described nor suggested previously. The longest C9orf7 protein isoform shares just 30% identity with the longest Drosophila Fwe isoform (Few(ubi)).
The present invention improves on the state of the art by identifying mammalian, particularly human, homologues of Fwe, thereby providing means and methods for diagnosis, prevention and therapy of cancer, and furthermore facilitating assay systems for identifying cancer drug development candidates.
dfwe gene has a single predicted homologue in mice: 5930434B04Rik (Accession number: MGI:1924317). The mouse C9orf7 gene occupies 11.2 kb on chromosome 2 (qA3). This gene shares 92% identity with the longest protein isoform of its human orthologue. Mouse Flower (mFwe) encodes six different transcripts, normally expressed at low levels in adult tissues, which are translated into four protein isoforms.
By expressing individual mouse C9orf7 isoforms in Drosophila to test their function in established competition assays, the present inventors have unexpectedly found that certain mammalian isoforms of Flower behave as Loser forms, establishing their role in cell competition mechanisms. Absence of the C9orf7 gene in mice results in normal development, morphology and growth, but C9orf7 knock-out mice show a very significant protection against skin carcinogenesis. Upon treatment with 7,12-dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA), C9orf7 knock-out mice show 60% reduction in the number of papillomas. 20% of the mice remain papilloma free after the standard 15 weeks treatment. In addition, the few papillomas that appear in the C9orf7 knock-out mice are less proliferative.
In other words, elimination of the C9orf7 gene specifically impairs cell competition driven malignant growth, but not normal growth, implying that certain pre-cancerous cells can misuse the C9orf7 code in order to proliferate and contribute to tumor formation.
In mice, C9orf7 isoforms 1 and 3 behave as Loser isoforms and some of these isoforms, especially C9orf7 1, are up-regulated in the tissue that surrounds a papilloma. It is inferred from the data presented herein that DMBA/TPA-induced skin papillomas—and by extension, naturally occurring carcinomas in mammals—use mammalian homologues of dFwe to grow at the expense of the surrounding normal skin.
Furthermore, the data presented herein suggest the utility of abrogating Fwe signalling either on a protein or nucleic acid level in order to deprive nascent tumors or pre-cancerous lesions of what appears to be an important mechanism of propagation. The importance of Fwe expression in cancer may well not be limited to early stage tumor formation. Recent results describe the up-regulation of competition related genes also for established tumors and implicate this mechanism in metastasis (Petrova et al., Communicative & Integrative Biology (2011) 4, 1-4).
A “pre-cancerous state” or a “pre-cancerous lesion” in the context of the present specification refers to tissue comprising a cell population having undergone de-differentiation, dysplasia, or any other detectable change of healthy tissue towards neoplasia, particularly malignant neoplasia (cancer).
Human homologue of Fwe sequence data:
SEQ ID NO 1 is Ensembl transcript ID ENST00000316948.
SEQ ID NO 2 is Ensembl transcript ID ENST00000291722.
SEQ ID NO 3 is Ensembl transcript ID ENST00000444798.
SEQ ID NO 4 is Ensembl transcript ID ENST00000535514.
SEQ ID NO 5 is Ensembl transcript ID ENST00000540581.
SEQ ID NO 6 is Ensembl transcript ID ENST00000542192.
SEQ ID NO 7 is Ensembl protein ID ENSP00000317121.
SEQ ID NO 8 is Ensembl protein ID ENSP00000291722.
SEQ ID NO 9 is Ensembl protein ID ENSP00000414495.
SEQ ID NO 10 is Ensembl protein ID ENSP00000444402.
SEQ ID NO 11 is Ensembl protein ID ENSP00000440832.
SEQ ID NO 12 is Ensembl protein ID ENSP00000444328.
Sequences of SEQ ID NO 1 to 6 correspond to the coding nucleic acid sequences encoding the six human Flower homologues. Sequences 007 to 012 correspond to the corresponding encoded proteins, respectively.
SEQ ID NO 13 corresponds to mRNA of C9orf7-202_ENST00000540581, from the ATG in 1st exon to the final nucleotide of its 3th exon (SEQ ID NO-5) RNAi target sequence. SEQ ID 013 has no known off-targets (no other 19-nucleotides sequences found similar to this in the human genome) and targets all coding isoforms of human Fwe.
SEQ ID NO 14 is an C-terminal extracellular loop comprised in SEQ ID NO 7, 8 or 10.
SEQ ID NO 15 is an extracellular loop between transmembrane domains 1 and 2.
SEQ ID NO 16 is an extracellular domain at the C-terminal of SEQ ID 11 and 12.
SEQ ID NO 17 is an extracellular loop between transmembranes 1 and 2 of SEQ ID 11 and 12.
According to a first aspect of the invention a method for diagnosing cancer, a tumor disease or a pre-cancerous state in a human subject is provided, comprising the steps of:
According to an alternative of this first aspect of the invention, a method for assigning to a biological sample a diagnostic score value is provided, comprising:
In one embodiment, said diagnostic score value relates to a likelihood of said sample representing a tumor tissue, particularly a carcinoma tissue.
In some embodiments, the method is performed ex-vivo.
In some embodiments, said biological sample is selected from the group comprising a blood sample, a plasma sample, a serum sample, a saliva sample, a biopsy sample, a tumor sample and a tissue sample.
In one embodiment, the presence of a nucleic acid identified by SEQ ID NO 2 and/or 6 is determined. In one embodiment, the presence of a protein identified by SEQ ID NO 8 or 12 is determined (these sequences represent Fwe(Loser)).
In one embodiment, the presence of a nucleic acid identified by SEQ ID NO 1 and/or 5 is determined. In one embodiment, the presence of a protein identified by SEQ ID NO 7 or 11 is determined (these sequences represent Fwe(Ubi)).
In some embodiments, the presence, location, and/or quantity of a nucleic acid sequence is determined by RT-PCR (reverse transcriptase polymerase chain reaction) or FISH (fluorescence in-situ-hybridization). RT-PCR allows for the precise determination of transcript levels in the sample. In one embodiment, an RT-PCR primer-probe combination is selected that amplifies a consensus sequence common to all coding sequences (SEQ ID NO 1 to 6). In one embodiment, this consensus sequence is the sequence of SEQ ID NO 13.
In one embodiment, an RT-PCR primer-probe combination is selected that amplifies a sequence specific for SEQ ID NO 1. In one embodiment, an RT-PCR primer-probe combination is selected that amplifies a sequence specific for SEQ ID NO 2. In one embodiment, an RT-PCR primer-probe combination is selected that amplifies a sequence specific for SEQ ID NO 3. In one embodiment, an RT-PCR primer-probe combination is selected that amplifies a sequence specific for SEQ ID NO 4. In one embodiment, an RT-PCR primer-probe combination is selected that amplifies a sequence specific for SEQ ID NO 5. In one embodiment, an RT-PCR primer-probe combination is selected that amplifies a sequence specific for SEQ ID NO 6.
In one embodiment, a “multiplex” set-up is chosen wherein primers and probes are provided that facilitate concomitant and specific detection of two, three, four, five or six sequences side-by-side within the same sample. While a certain amount of work is necessary to devise primer-probe combinations, the level of experimentation to arrive at multiplex RT-PCR combinations is well within the skill of the skilled artisan. For example, US2011136178 (hereby incorporated by reference) provides modified primers facilitating the design of multiplex RT mixes.
In one embodiment, an RT-PCR primer-probe combination is selected that amplifies sequences specific for SEQ ID NO 1 and 5. In one embodiment, an RT-PCR primer-probe combination is selected that amplifies sequences specific for SEQ ID NO 2 and 6.
In one embodiment, FISH is used to determine the localisation and distribution of nucleic acid sequences encoding the human homologue of Flower in a tissue sample.
For protocols on FISH, see Müller et al. Cold Spring Harbor Protocols 2007 (doi:10.1101/pdb.prot4730); Raj et al. 2008, Nature Methods 5, 877-879 doi:10.1038/nmeth.1253, and references cited therein.
In an alternative of this aspect of the invention, the presence, location, and/or quantity of a protein identified by one of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17 (the human homologue of Flower protein sequences) is determined. Any of the methods known to the skilled artisan for determining the presence, location or quantity of a specific protein in a tissue sample or other biological specimen obtainable ex-vivo can be employed. A ligand raised against and/or specific for the target protein, having a high affinity for the target protein (typically characterized by a dissociation constant in the range of 10E-7 to 10E-9 mol/l or lower) is brought into contact with the sample under conditions allowing for the specific binding of the ligand to its target, the sample is washed and the presence of bound ligand, or its quantity, is determined. In some embodiments, the ligand is an antibody (particularly a monoclonal antibody), an antibody-fragment or an antibody-like molecule.
In some embodiments, binding is determined by measuring the signal of a label attached to the ligand. Examples of suitable labels are fluorescent molecules such as dye molecules or fluorescent proteins, radioactive labels such as a radioisotope, or enzymes capable of mediating a reaction that can be employed to quantify the presence of the ligand directly, such as by luminescence (e.g., luciferase) or conversion of a suitable substrate to a dye molecule (e.g., peroxidase), or by catalyzing the attachment of reporter molecules (e.g., SNAP-tag).
Fluorescently labeled antibodies are particularly suitable to practice the method of the invention, as far as detection of protein is the objective.
According to one embodiment, an antibody specific for an extracellularly exposed amino acid sequence of a protein identified by one of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17 is employed for determination of protein presence, location, and/or quantity.
In one embodiment, a ligand, particularly an antibody, specific for an extracellularly exposed amino acid sequence of SEQ ID NO 7 is employed. “Specific” in the context of this embodiment refers to the ability of this ligand to bind to the extracellular part of SEQ ID NO 7, but not to at least one of SEQ ID NO 8, 9, 10, 11 or 12, thus enabling discrimination of cells or tissues that express SEQ ID NO 7 from those that express SEQ ID NO 8, 9, 10, 11 or 12. In some embodiments, a ligand is employed that specifically binds to an extracellular part of only one of the proteins identified by SEQ ID NO 7, 8, 9, 10, 11 or 12, and to none of the others. Such ligand is referred to as “single isoform specific ligand”.
According to one embodiment, 2, 3, 4, 5 or 6 single isoform specific ligands specific for any combination of proteins SEQ ID NO 7, 8, 9, 10, 11 and 12 are employed.
In one embodiment, the disease to be diagnosed is a neoplastic disease. In one embodiment, the disease is a carcinoma (cancer of epithelial origin).
According to another alternative of this first aspect of the invention, the method is practiced in-vivo and the presence of tissue expressing a human homologue of Flower as specified by one of the sequences of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17 is detected by binding of a ligand to an extracellular amino acid sequence of any or all of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17, and binding is determined by detecting a label attached to said ligand. Among the suitable ligands for this in-vivo alternative of the diagnostic method of the invention are radiolabelled ligands, ligands labeled by near-infrared dye molecules, PET- or SPECT-tracer labeled ligands or ligands labeled by NMR contrast agents such as gadolinium atoms. In some embodiments, such ligand is an antibody.
According to a second aspect of the invention, a ligand capable of selectively binding to a protein identified by one of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17, is provided, wherein said ligand is covalently attached to a detectable label or wherein the ligand comprises a detectable label.
Alternatively, the ligand comprises the detectable label. In some embodiments, the detectable label is part of the ligand structure. In one embodiment, a radioisotope is comprised in an amino acid incorporated in a peptide chain forming said ligand.
In some embodiments, the label the detectable label is a radioisotope or dye molecule, and is attached to the ligand covalently or via a covalently attached chelator molecule such as DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7-triazacyclononane-N,N′,N″-triacetic acid), HYNIC (6-Hydrazinopyridine-3-carboxylic acid) or others. In some embodiments, a radioactive label is attached to the ligand as a nanoparticle.
According to one embodiment of this aspect of the invention, the detectable label is a radiolabel for PET (positron emission tomography) or SPECT (Single-photon emission computed tomography), such as one of the radioisotopes carbon-11, nitrogen-13, oxygen-15, fluorine-18, gallium-68, technetium-99m, indium-111 or iodine-123, iodine-124. The radiolabel may be comprised in the ligand by incorporation or covalent coupling to the peptide itself, or a carrier molecule attached thereto.
In some embodiments, the detectable label is a near infrared fluorescent dye. One example for such dye is an indotricarbocyanine dye. Near infrared dyes have been described, inter alia, by Umezawa (J. Am. Chem. Soc. (2008) 130, 1550-1551) and are available, for example, from Amersham/GE Healthcare (Little Chalfont, GB), mivenion GmbH (Berlin, DE), and LI-COR Biosciences (Lincoln, Nebr., USA).
In some embodiments, the ligand is an antibody, an antibody-fragment, an antibody-like molecule, or a nucleic acid aptamer.
Methods for generating antibodies against a protein identified by one of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17, particularly the extracellular part of SEQ ID NO 7, 8, 9, 10, 11 and 12, are known in the art. They include, for example, immunization of mice with such protein, or soluble parts thereof.
An antibody fragment may be the Fab domain of an antibody (the antigen binding region of an antibody) or a single chain antibody (scFv), which is a fusion protein consisting of the variable regions of light and heavy chains of an antibody connected by a peptide linker. An antibody-like molecule may also be a repeat protein, such as a designed ankyrin repeat protein (Zurich Univ., Switzerland and Molecular Partners AG, Zurich, Switzerland; see US20120142611 (A1), incorporated by reference herein). An antibody fragment or an antibody-like molecule may be manufactured by methods such as recombinant protein expression.
Suitable ligands for practicing the invention may also be developed by evolutive methods such as phage display, ribosome display or SELEX, wherein polypeptides or oligonucleotides (aptamers) are selected according to their binding affinity to a target of interest. Additionally, ligands of higher affinity may be identified by reiterative rounds of evolution and selection of the amino acid sequence or nucleotide sequence.
According to one embodiment of the invention, a ligand as set forth above is provided, which comprises or is covalently linked to a radioisotope emitting beta or gamma radiation. A radioisotope such as carbon-11 for example may form part of the peptide backbone, in embodiments where the ligand is a polypeptide, e.g. an antibody. Alternatively, a radioisotope is attached to the side chain of an amino acid constituting the ligand, such as may be, by way of non-limiting example, a tyrosine, phenylalanine or histidine having an iodine radioisotope attached to its aromatic ring.
According to an alternative to this second aspect of the invention, the ligand according to this second aspect of the invention, in general form or in any of the specified embodiments, is provided for use in a method for detecting cancer or a precancerous state in a patient.
In some embodiments, the patient is a human being. In some embodiments, the method is practiced ex-vivo. In some other embodiments, the method is practiced in-vivo.
According to a third aspect of the invention, a nucleic acid molecule specifically hybridizing to a nucleic acid sequence identified by one of SEQ ID NO 1, 2, 3, 4, 5, 6 or 13 is provided, said nucleic acid molecule being covalently attached to a detectable label.
In some embodiments of this aspect of the invention, the nucleic acid molecule comprises a fluorescent dye molecule, for example for use as a probe in real-time PCR methods such as RT-PCR or for use as a FISH probe.
According to an alternative to this third aspect of the invention, the nucleic acid molecule according to this third aspect of the invention is provided for use in a method for detecting cancer or a precancerous state in a patient.
In some embodiments, the patient is a human being. In some embodiments, the method is practiced ex-vivo. In some other embodiments, the method is practiced in-vivo.
According to a fourth aspect of the invention, a ligand capable of selectively binding to a protein identified by one of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17 is provided for use in a method for preventing or treating a disease, particularly cancer, more particularly carcinoma or a pre-cancerous state.
In some embodiments, the ligand is an antibody, an antibody-fragment, an antibody-like molecule, or a nucleic acid aptamer. In some embodiments, the ligand is a human or humanized immunoglobulin gamma or a fragment thereof. In some embodiments, the ligand is an antibody or a fragment of an antibody raised against a protein identified by one of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17.
In some embodiments embodiment of this fourth aspect of the invention, the ligand is covalently attached to a therapeutic radioisotope or a cancer drug or toxin. Non-limiting examples for therapeutic radioisotopes are phosphorus-32, strontium-89, ytrrium-90, iodine-125 and -131, samarium-153, erbium-169, lutetium-177 and rhenium-186/188. Non-limiting examples for toxins and cancer drugs are ricin toxin, diphtheria toxin, anthrax toxin, pro-aerolysin, pseudomonas exotoxin, shigella toxin, cone snail neurotoxin, auristatin, doxorubicin, daunorubicin, taxol, irinotecan, vincristine, vinblastine, cisplatin, carboplatin, oxaliplatin and ifosfamideetoposide.
Alternatively, the antibody is provided as is, i.e. without attachment. As the examples of the present description illustrate, abrogation of the biological function of mammalian homologues of Flower is sufficient to prevent cancer from developing under certain circumstances, or for certain types of tumor.
The binding of ligand results in blocking the role of the Flower homologue in mediating competition, thus inhibiting tumor growth and spreading of pre-cancerous or cancerous cells within the tissue.
The ligands—particularly antibodies—described herein are useful for the diagnosis, prevention and therapy of cancer, particularly carcinoma. According to one embodiment of any ligand of the present invention, the ligand binds to a protein identified by one of SEQ ID NO 7, 8, 9, 10, 11, 12, 14, 15, 16 and/or 17 with an dissociation constant of below 50 nmol/l.
According to one embodiment of any of the aspects of the invention described herein which features a ligand to one of SEQ ID NO 7, 8, 9, 10, 11 or 12, the ligand is raised against the extracellular domains of a human protein isoform of Fwe, for example the extracellular C-terminal (SEQ ID NO 14) of SEQ ID NO 7, 8 or 10 or the predicted extracellular loops between transmembranes 1 and 2 (SEQ ID NO 15). Also the extracellular domain at the C-terminal (SEQ ID NO 16) of sequences ID 11 and 12 or the predicted extracellular loops between transmembranes 1 and 2 (SEQ ID NO 17) of sequences ID 11 and 12.
Antibodies or antibody fragments are particularly suitable embodiments of any ligand mentioned herein. Human (or humanized) immunoglobulin gamma antibodies are particularly useful. Humanized antibodies are antibodies derived from other species than homo sapiens, the protein sequences of which are modified to increase their similarity, and thus tolerability and physiologic function, in humans (Riechmann et al. (1988), Nature 332, 323-327 and publications citing this article).
According to a fifth aspect of the invention, an inhibiting nucleic acid molecule having a sequence complementary to one of SEQ ID NO 1, 2, 3, 4, 5, 6 or 13 and inhibiting the expression as a protein of a nucleic acid sequence identified by one of SEQ ID NO 1, 2, 3, 4, 5, 6 or 13 is provided for prevention or therapy of disease. Such inhibiting nucleic acid silences or “knocks down” the genetic message encoded by the sequences SEQ ID NO 1 to 6.
The art of silencing or “knocking down” genes, by degradation of mRNA or other effects, is well known. Examples of technologies developed for this purpose include siRNA, miRNA, shRNA, shmiRNA, and dsRNA. A comprehensive overview of this field can be found in Perrimon et al, Cold Spring Harbour Perspectives in Biology, 2010, 2, a003640.
Identity in the context of the present invention is a single quantitative parameter representing the result of a sequence comparison position by position. Methods of sequence comparison are known in the art; the BLAST algorithm available publicly is an example.
“Capable of forming a hybrid” in the context of the present invention relates to sequences that under the conditions existing within the cytosol of a mammalian cell, are able to bind selectively to their target sequence. Such hybridizing sequences may be contiguously reverse-complimentary to the target sequence, or may comprise gaps, mismatches or additional non-matching nucleotides. The minimal length for a sequence to be capable of forming a hybrid depends on its composition, with C or G nucleotides contributing more to the energy of binding than A or T/U nucleotides, and the backbone chemistry.
An inhibiting nucleic acid according to this fifth aspect may also be encoded an expression vector comprising a sequence encoding an interfering ribonucleic acid oligomer as described in the preceding paragraphs. Optionally, the sequence may be under the control of a promoter operable in mammalian cells. Such expression vectors facilitate production of an interfering RNA within the cell. Methods for making and using such expression vectors are known in the art.
Alternatively, an inhibiting nucleic acid molecule according to the above aspect of the invention may be a single-stranded or double-stranded antisense ribonucleic or deoxyribonucleic acid, comprising sequences complementary to an operon expressing one of SEQ ID NO 1, 2, 3, 4, 5, or 6 described above. Such operon sequences may include, without being restricted to, intron, exon, operator, ribosome binding site or enhancer sequences. Such antisense molecules may be 12-50 nucleotides in length.
“Nucleotides” in the context of the present invention are nucleic acid or nucleic acid analogue building blocks, oligomers of which are capable of forming selective hybrids with RNA oligomers (specifically with a sequence tract comprised in one or all of SEQ ID NO 1, 2, 3, 4, 5, or 6, such as a sequence tract comprised in SEQ ID NO 13) on the basis of base pairing. The term nucleotides in this context includes the classic ribonucleotide building blocks adenosine, guanosine, uridine (and ribosylthymin), cytidine, the classic deoxyribonucleotides deoxyadenosine, deoxyguanosine, thymidine, deoxyuridine and deoxycytidine. It further includes analogues of nucleic acids such as phosphotioates, 2′O-methylphosphothioates, peptide nucleic acids (PNA; N-(2-aminoethyl)-glycine units linked by peptide linkage, with the nucleobase attached to the alpha-carbon of the glycine) or locked nucleic acids (LNA; 2′O, 4′C methylene bridged RNA building blocks). The hybridizing sequence may be composed of any of the above nucleotides, or mixtures thereof.
The inventive inhibiting nucleic acid is able to abrogate the expression of one, two, three, four, five or all of the proteins identified by one of SEQ ID NO 7, 8, 9, 10, 11 and 12.
Such inhibiting nucleic acid molecule according to the fifth aspect of the invention may be a nucleic acid directed against and hybridizing to one, several or all of SEQ ID NO 1, 2, 3, 4, 5 or 6, preferentially with neutralizing properties. It may be a single-stranded or double-stranded ribonucleic acid oligomer or a precursor thereof, or a deoxyribonucleic acid or analogue thereof, comprising a sequence tract complementary to one, several or all of SEQ ID NO 1, 2, 3, 4, 5, or 6.
In one embodiment, the inhibiting nucleic acid molecule hybridizes to SEQ ID NO. 13.
In some embodiments, the hybridizing sequence of the inhibiting nucleic acid of the invention comprises 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides.
In some embodiments, the hybridizing sequence is at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% identical to the reverse complimentary sequence of one, several or all of SEQ ID NO 1, 2, 3, 4, 5, 6 or 13. In some embodiments, the hybridizing sequence comprises deoxyribonucleotides, phosphothioate deoxyribonucleotides, LNA and/or PNA nucleotides or mixtures thereof.
In some embodiments, the hybridizing sequence comprises ribonucleotides, phosphothioate and/or 2′-O-methyl-modified phosphothioate ribonucleotides.
In some embodiments, the hybridizing sequence comprises deoxyribonucleotides, phosphothioate deoxyribonucleotides, phosphothioate ribonucleotides and/or 2′-O-methyl-modified phosphothioate ribonucleotides.
In some embodiments, the inhibitory nucleic acid molecule comprises a cholesterol moiety or a peptide. In some embodiments, the hybridizing sequence is covalently attached to a cholesterol moiety or a peptide. Alternatively, the peptide may be part of a nucleic acid-peptide complex held together without covalent attachment by electrostatic or hydrophobic interaction. In some embodiments the inhibitory nucleic acid molecule comprises a peptide having or consisting of a TAT translocation sequence or a functional equivalent thereof.
In some embodiments, the above ribo- or deoxyribonucleotide moieties, optionally protected against degradation by phosphothioate linkage and/or 2′O-methyl ethers, and/or LNA or PNA moieties, are combined with cholesterol or peptide targeting and packaging moieties.
According to yet another aspect of the invention, a pharmaceutical composition is provided, wherein said pharmaceutical composition comprises a ligand, an inhibiting nucleic acid molecule and/or an expressed nucleic acid molecule according to any of the aspects of the invention outlined above.
In one embodiment, the pharmaceutical composition comprises a ligand, an inhibiting nucleic acid molecule and/or an expressed nucleic acid molecule specific for one isoform of human Fwe only.
In one embodiment, the pharmaceutical composition comprises one or several ligand(s), one or several inhibiting nucleic acid molecule(s) and/or one or several expressed nucleic acid molecule(s) so that the pharmaceutical composition in total inhibits several or all isoforms of human Fwe. The data of the present invention show that abrogation of all Fwe signalling in the mouse carcinoma model confers great advantages. Thus, according to this embodiment, the therapeutic approach is to downregulate all Fwe isoforms, (as in the KO mouse of the examples), targeting, for example, their conserved sequences on protein or nucleic acid level, thus reducing or suppressing the expression of all isoforms in the tissues surrounding the tumor.
In one embodiment, the pharmaceutical composition comprises one or several ligand(s), one or several inhibiting nucleic acid molecule(s) and/or one or several expressed nucleic acid molecule(s) so that the pharmaceutical composition in total inhibits the isoforms of human Few encoded or represented by SEQ ID NO. 2, SEQ ID NO. 3 and/or SEQ ID NO. 6, and/or SEQ ID NO. 7, SEQ ID NO. 8 and/or SEQ ID NO. 12, respectively. These are the closest relatives, measured by nucleic acid or protein identity or similarity, to murine isoforms 1 and 3, which the examples of the present invention illustrate are a “loser” form of Fwe (see
The pharmaceutical compositions of the invention are particularly useful for the prevention or treatment of cancer.
Similarly within the scope of the present invention is a method of preventing or treating cancer in a patient in need thereof, comprising administering to the patient a ligand, inhibiting nucleic acid molecule or pharmaceutical composition according to the invention.
Similarly, a dosage form for the prevention or treatment of cancer is provided, comprising a ligand, inhibiting nucleic acid molecule or pharmaceutical composition according to one of the above aspects of the invention. Dosage forms may be for enteral administration, such as nasal, buccal, rectal, transdermal or oral administration, or as an inhalation form or suppository. Alternatively, parenteral administration may be used, such as subcutaneous, intravenous, intrahepatic or intramuscular injection forms. Optionally, a pharmaceutically acceptable carrier and/or excipient may be present.
Furthermore, a method is provided for identifying a candidate compound for development of a drug suitable for the prevention and/or treatment of cancer disease is provided, said method comprising:
According to another aspect of the invention, a method for identifying a candidate compound for development of a drug suitable for the prevention and/or treatment of cancer disease is provided, said method comprising:
A compound that inhibits the expression of the mammalian homologues of Flower is a drug candidate for the prevention and/or treatment of cancer.
Wherever alternatives for single features such as, for example, an isotype protein or coding sequence, ligand type or medical indication are laid out herein as “embodiments”, it is to be understood that such alternatives may be combined freely to form discrete embodiments of the invention disclosed herein. Thus, any of the alternative embodiments for a detectable label may be combined with any of the alternative embodiments of ligand and these combinations may be combined with any medical indication or diagnostic method mentioned herein.
The invention is further illustrated by the following examples and figures, from which further embodiments and advantages can be drawn.
adult mice measured by real-time quantitative PCR. The data represent average mRNA expression level relative to the expression of the 18S rRNA gene of three independent experiments. Bars are means±s.e.m. Y-axes are linear in scale, the scale for A-D is 10E-4 for the upper most bar and 0 for the lower end. The dotted lines mark the level of expression of mFwe 1 and mFwe 2 in papilloma-surrounding skin of mice treated with DMBA/TPA, which is presented the following table:
Materials and methods used in Examples:
The Fwe knock-out mouse was developed using genOway technical services (genOway, Lyon, France). The targeting vectors for generation of Fwe null alleles were constructed by using genomic DNA (21.3 kb) that encompasses the entire murine Fwe gene region isolated from a 129Sv/Pas miniBAC library. The targeting vector used for homologous recombination consisted of asymmetric homology arms isogenic with the ES cell line of 129Sv/Pas genetic background. The linearized targeting construct (40 μg) was introduced into 129Sv/Pas mouse embryonic stem cells (5×106 cells) by electroporation (260 V, 500 μF). Genomic DNA extracted from the amplified ES cell clones was screened for homologous recombination by both PCR and Southern blot strategies. The 3′ Southern blot screening is based on digestion of genomic DNA with NheI and hybridization of an external 523 bp probe downstream of the 3′ homology sequence of the Fwe targeting vector. ES cells from positive ES cell clones were microinjected in C57BL/6 blastocysts, which were then introduced into pseudo-pregnant OF1 female mice. Highly chimaeric males (80% chimaerism) were mated with C57BL/6 wild-type females to investigate whether the recombined ES cells contribute to the germ-line. The resulting F1 animals that showed agouti coat color were heterozygous for the recombined allele and were in 1:1 mixed genetic background C57BL/6:129 Sv/Pas. To generate constitutive knock-out mice the loxP-flanked exon 3 (floxed allele) was removed by crossing to a germline::Cre deleter mouse. Constitutive Fwe knockout mice were screened by PCR using the following primers: FW 5′-CTAACTACCCAAGCATCCTG-3′ (SEQ ID NO 18), RVex4 5′-CGCAGTTGAAGAGTCCAGAG-3′ (SEQ ID NO 19), and RVex3 5′-TACACCAAAGAATGACCCAC-3′ (SEQ ID NO 20), which yield 685 and 354 bp products for the mutant and wild-type alleles, respectively.
The mice used in this study were housed in specific pathogen-free animal facility at the Spanish National Cancer Research Center (Madrid). The animals were maintained by crossing to mice of C57BL/6J genetic background. The experiments were performed using littermate mice.
The back skin of two-to three-month old mFwe(+/+), mFwe(Δex3/+) and mFwe(Δex3/Δex3) littermate mice was shaved and one day later was painted with a single dose of 25 μg of 7,12-dimethylbenz[a]anthracene (Sigma) dissolved in 200 μl acetone. Two days later, tumor growth was promoted by applying 12.5 μg of 12-O-tetradecanoylphorbol-13-acetate (Calbiochem) dissolved in 200 μl acetone twice a week for a period of 15 weeks. The mice were observed every three days and size, number and characteristics of the skin lesions were annotated. Measurement of tumor size was done twice per week using a digital caliper.
Skin papillomas and surrounding skin were fixed in neutral-buffered formalin during 24 hours and subsequently embedded in paraffin. Sections of ˜5 μm were cut and stained with hematoxylin and eosin following standard procedures. For immunohistochemistry, ˜5 μm sections from formalin-fixed, paraffin-embedded tissue samples were incubated with anti-Ki67 antibody (TEC-3, DAKO). The quantification of immunohistochemistry samples was performed automatically using AxioVision software (Carl Zeiss, Germany) by measuring the area occupied by Ki67-positive cells in papillomas and the papillomasurrounding epidermis (1000 μm at each side of a papilloma).
Total RNA of mouse tissues was extracted using Trizol reagent (Invitrogen) following the manufacturer's instructions. It was treated with DNase I (Promega) and additionally purified using Qiagen RNeasy columns. cDNA was synthesized using SuperScript II reverse transcriptase (Invitrogen). Semi-quantitative PCR was done using mFwe-specific primer that hybridizes to mFwe exon 3 5′-CTCTTCAACTGCGTCACTAT-3′ (SEQ ID NO 21), a primer that hybridizes to mFwe exon 4 5′-TGCCCACTGCTATCAAATAA-3′ (SEQ ID NO 22) and Gapdh-specific primers 5′-GTATGTCGTGGAGTCTACTG-3′ (SEQ ID NO 23) and 5′-TCATCATACTTGGCAGGTTT-3′ (SEQ ID NO 24). To quantify the abundance of mFwe transcripts in wild-type mice treated with the DMBA/TPA carcinogenesis protocol, total RNA was extracted separately from skin papillomas and the corresponding papilloma-surrounding skin and was analyzed by real-time quantitative PCR. The expression level of each transcript in both samples was compared to its expression in the skin of age-matched wild-type mice not treated with DMBA/TPA. Papilloma-surrounding skin was a normal-looking skin located within a diameter of approximately 1 cm from a papilloma. To determine the expression level of mFwe transcripts in different tissues of wild-type mice, total RNA was extracted from skin, brain, liver, pancreas, small intestine, colon, muscle, heart, spleen and eye tissue samples and was analyzed by real-time quantitative PCR. Real-time quantitative PCR was performed using 0.5 μl of cDNA prepared from 3 μg of total RNA, 2× Power SYBR green PCR master mix (Applied Biosystems) and BioRad Single-Color PCR detection apparatus. All PCR reactions were set up in triplicates and the experiments were performed with at least three different samples. Data were analyzed using the comparative CT method (Schmittgen and Livak, (2008), Nat Prot 3, 1101-1108). The Ct values of samples and controls were normalized to the expression level of 18S endogenous housekeeping gene. The primers used were 18S-Fw 5′-GTAACCCGTTGAACCCCATT-3′ (SEQ ID NO 25), 18S-Rv 5′-CCATCCAATCGGTAGTAGCG-3′ (SEQ ID NO 26), mFwe1-Fw 5′-TCCACACTTCTCTGGTTCTG-3′ (SEQ ID NO 27), mFwe1-Rv 5′-GTGAGTACTGCTGTCTAGCC-3′ (SEQ ID NO 28), mFwe2-Fw 5′-CGATGCCATTTCTTATGCTC-3′ (SEQ ID NO 29), mFwe2-Rv 5′-TGACACTCAGTCTTCTCCAG-3′ (SEQ ID NO 30), mFwe3-Fw 5′-CAAACACAGTAGCTGAGAAGG-3′ (SEQ ID NO 31), mFwe3-Rv 5′-TAGAGGGAAATGGTGTTTCTG-3′ (SEQ ID NO 32), and mFwe4-Fw 5′-GTTTGCTAAATCCTGGGTGTC-3′ (SEQ ID NO 33), mFwe4-Rv 5′-GCGTTCATGATCATCCACAC-3′ (SEQ ID NO 34).
cDNA encoding mFwe isoforms was amplified from total spleen cDNA of adult C57BL/6 mice using the primers: mFwe1 (5′-GCAGCGTTTAGCATGAG-3′ (SEQ ID NO 35), 5′-TCACCCGCAGTAGAAGAC-3′ (SEQ ID NO 36)), mFwe2 (5′-GCAGCGTTTAGCATGAG-3′ (SEQ ID NO 37), 5′-CTCGAAAGTCTCCGCCA-3′ (SEQ ID NO 38)), mFwe3 (5′-GCAGCGTTTAGCATGAG-3′ (SEQ ID NO 39), 5′-AAATGGTGTTTCTGTTCGG-3′ (SEQ ID NO 40)), and mFwe4 (5′-AGCGGCTCGGGCGCCGCCGGA-3′ (SEQ ID NO 41), 5′-CTCGAAAGTCTCCGCCA-3′ (SEQ ID NO 42)). A haemagglutinin (HA) tag sequence was included at the 3′ end of each mFwe cDNA by PCR. The cDNAs were cloned into pUASp vector (DGRC) using BamHI and XbaI restriction sites (for mFwe1-HA and mFwe3-HA), Xba I sites (for mFwe2-HA), or NotI and XbaI sites (for mFwe4-HA). Microinjection of these cDNA constructs into fly embryos was performed according to standard protocols.
Micro-computer tomography analyses were done in the Molecular Imaging Unit of CNIO using eXplore Vista micro PET-CT (GE Healthcare, United Kingdom) and MMWKS Vista-CT 4.7 software following standard procedures.
Transgenic Flies and Clone Induction mFwe isoforms transgene expression in Drosophila, gain-of-function assays and their analyses were performed as described previously (Rhiner et al., ibid).
Areas of EGFP-marked clones and wing discs were quantified using Adobe Photoshop (Adobe Systems Inc.). Quantification of Ki67-stained sections of papillomas and papilloma-surrounding skin (five mice per genotype) was performed automatically using AxioVision software (Carl Zeiss, Germany). All papillomas per mouse were analyzed. Papilloma-surrounding skin is normal-looking skin that occupies 1000 μm at each side of the tumor. The data represent Ki67-positive area as a percentage of total area measured. For quantification of cell proliferation in wild-type and knock-out mice not treated with DMBA/TPA, Ki67-positive cells were counted manually in 20 photos at 40× magnification per mouse. The data represent number of Ki67-positive cells per μm2 measured. Quantification of apoptosis in sections of papillomas and papilloma-surrounding skin stained for activated caspase 3 (three mice per genotype) was performed manually by counting the number of activated caspase 3-positive cells in photos at 40× magnification that comprise all papillomas and 1000 μm of normal skin at each side of every papilloma. The data represent number of activated caspase 3-positive cells per μm2 measured.
Statistical analyses were performed by Student's t, chi, and Mann-Whitney tests using Excel (Microsoft Office) or GraphPad Prism (GraphPad Software). For tumor-free curves, the log-rank test was used. Data represent means±s.e.m.
Drosophila Flower belongs to a unique superfamily of small proteins called CG6151-P, which are conserved from fungi to humans. All homologues share the putative conserved protein domain CG6151-P (Marchler-Bauer et al., (2009), Nucl Acids Res 37, D205-10). Except for dFwe, the function of the remaining homologues is unknown. 5930434B04Rik is the single predicted homologue of dFwe sharing 35% identity at the protein sequence level. The 5930434804Rik locus produces six alternatively spliced protein coding transcripts (
To analyze the expression of the mFwe splice variants in various tissues of adult C57BL/6 mice, we performed real-time quantitative PCR. We grouped mFwe mRNA splice variants into four different classes—mFwe1, mFwe2 (mFwe2a, mFwe2b, mFwe2c), mFwe3, and mFwe4—because these different coding sequences generate four mFwe protein isoforms (
To find out whether mFwe protein isoforms could have a function similar to that of dFwe(LoseA/B) proteins, we tested the effect of their overexpression on cell survival. A previous study showed that overexpression of dFwe(LoseA/B) in Drosophila S2 cultured cells or in clones of cells in Drosophila larvae epithelia induced cell death and clone disappearance (Rhiner et al., ibid). When we overexpressed mFwe isoforms in several types of mammalian cells in culture, we did not observe a similar effect (data not shown). Thus, we assayed the function of mFwe isoforms by expressing them as transgenes in Drosophila (
Previous studies in Drosophila showed that the expression of two of the dfwe alternative transcripts, dfwe(LoseA) and dfwe(LoseB), is restricted specifically to cells of lower fitness, for example those cells that surround dMyc overexpressing clones of cells (Rhiner et al., ibid). We reasoned that, similarly, mammalian models of tumorigenesis could provide situations where cells of different fitness levels are confronted within a tissue. Therefore, measuring the expression level of mFwe transcripts in a tumor and the surrounding non-affected tissue could provide information on the fitness status of tumor cells relative to the adjacent normal cells. Thus, we checked whether the mFwe transcripts were differentially expressed in papillomas and surrounding normal tissue after subjecting C57BL/6 mice to the DMBA/TPA carcinogenesis protocol (
To further study the possible function of mFwe as a marker of potentially less fit cells in vivo, we generated mFwe knock-out mice by targeted deletion of exon 3, which affects all isoforms (
We verified the absence of mFwe mRNA expression in mFwe(Dex3/Dex3) mice and the reduced mFwe mRNA expression in mFwe heterozygous mice (
mFwe-deficient mice develop and grow normally (
Since reduction of dFwe expression can slow down the expansion of dMyc-overexpressing pretumoral clones of cells without affecting normal tissue growth, we sought to test whether lack of mFwe could have a beneficial effect on tumorigenesis in mice. Therefore, we subjected constitutive mFwe knock-out, mFwe heterozygous and wild-type mice to the DMBA/TPA skin carcinogenesis protocol, which induces skin papilloma formation. (
The number of papillomas that appeared in mFwe-deficient mice was strongly reduced (1.5 papillomas/mouse at week 15) compared to the number of papillomas observed in wild-type (3.9 papillomas/mouse at week 15) or mFwe heterozygous (5 papillomas/mouse at week 15) littermates (
To understand how deficiency of mFwe could account for the reduced number of skin papillomas induced by DMBA/TPA, we analyzed papillomas and papilloma-surrounding skin both macroscopically and at the tissue/cell level.
Examination of tumor samples according to previous classification criteria (Klein-Szanto, (1997), Pathology of Neoplasia and Preneoplasia in Rodents, Vol. 2. pp. 1-18) and staining for the keratinocyte differentiation marker cytokeratin 10, revealed that papillomas from the three experimental groups were of similar size and consisted of well-differentiated, hyperplastic lesions with no atypical cells, or with very few atypical cells in the basal layer (
To evaluate whether the reduced number of papillomas observed in the mFwe-deficient mice could reflect compromised proliferation of mFwe-deficient pretumoral cells, we stained papillomas and papilloma-surrounding tissue of wild-type and mFwe-deficient mice with Ki67, a marker of proliferating cells (
In Drosophila, increased expression of dFwe(LoseA/B)triggers cell non-autonomous apoptosis (Rhiner et al., 2010). To check whether expression of mFwe affects apoptosis levels in papilloma-surrounding skin relative to papillomas, we measured the number of activated caspase 3-positive cells in papillomas and papilloma-surrounding skin of wild-type and mFwe(Dex3/Dex3) mice (
The examples of the present description show for the first time data about the possible function of mouse Flower (mFwe)—the predicted homologue of the Drosophila cell competition gene dFlower. Like dFwe(LoseA/B) isoforms, mFwe 1 and mFwe 3 induce non-autonomous apoptosis when over-expressed in Drosophila wing imaginal disc cells: apoptosis was only observed when these proteins were overexpressed in clones of cells in the epithelial tissue, whereas no cell death was triggered if the entire tissue overexpressed mFwe1 or mFwe3 (
In Drosophila, cells of higher fitness use the Flower code to proliferate by inducing expression of dFwe(LoseA/B) in the surrounding loser cells (Rhiner et al., 2010). Similarly, we observe higher expression of certain mFwe isoforms, mainly in papilloma-surrounding skin compared to papillomas (
Here, we find that during skin papilloma formation mFwe 1 and mFwe 2 isoforms increase significantly their expression (
Another indication of a functional conservation between these proteins is our finding that mFwe deficiency reduces the capacity of skin papilloma cells to proliferate (
In addition, we report that papilloma-surrounding skin, where the “Lose”-like mFwe 1 isoform is upregulated, shows increased number of apoptotic cells as compared to papillomas in both wild-type and mFwe(Δex3/Δex3) mice (
In summary, we provide evidence that mFwe deficiency specifically impairs skin papilloma formation and proliferation, without affecting normal tissue growth.
Human epithelial cancers originate as a result of successive accumulation of genetic alterations in the tissue. Clonal expansion of mutant cells is necessary for the fixation of additional mutations and subsequent tumor formation. It is proposed that an active process of cell selection determines which cell persists in a tissue and forms a tumor. Such cell selection is based on a cell's fitness status, where a mutant cell of higher fitness can proliferate at the expense of cells of lower fitness, such as normal cells or cells carrying other types of mutations. The process of clonal expansion of mutant cells that causes no visible morphological change in the tissue is referred to as “field cancerization”. This term was first used in the clinic to explain the appearance of multiple primary tumors in the same region of a tissue or the local recurrence of secondary tumors following surgical resection. Field cancerization precedes tumor formation and is reported to occur in a wide variety of epithelial cancers. The present application provides means and methods to detect such cancer cells before a tumor is formed by facilitating biomarkers of cancerization fields. By applying antibodies or similar ligands for detecting and binding to the pretumor cell clones, the formation of cancer fields may be detected and inhibited, so that a tumor never forms. Cancer treatment at the earliest possible stage is the best option, but such therapy is precluded The present invention thereby facilitates the detection and therapy of early pretumoral stages of cancer.
The tumor samples of human origin were procured from Dr. Davide Soldini, Zurich University Hospital, and Ohio State University Medical Centre, James Cancer Center. Briefly 4 lung tumor samples, 1 breast tumor sample, 1 colon tumor sample, 1 urinary bladder tumor sample and 2 head and neck tumor samples along with the respective host tissue from tumor boundary and healthy tissue samples from the respective patients were analyzed for the expression of the above mentioned flower isoforms using qPCR. The qPCR was conducted using a custom made, commercially available kit from Invitrogen catalog-#-4331182 which performs qPCR for the cDNA sequences 1) NM—001135775.2, 2) NM—001242369.1, 3) NM—001242370.1 and 4) NM—017586.3 representing the cDNA sequences coded by the transcripts ENST00000291722, ENST00000540581, ENST00000542192 and ENST00000316948 respectively. The qPCR was conducted as per the manufacturer's protocol in the total RNA isolated from A) the tumor tissue B) the tumor boundary tissue and C) the healthy tissue from the respective patient.
The 4 different isoforms of Flower gene represented by the 4 transcript sequences ENST00000316948, ENST00000291722, ENST00000540581 and ENST00000542192 were characterized as the FLOWER(UBI) and FLOWER(LOSE) isoforms in MCF-7 and HCT human cancer cell lines of breast and colon origin. We hypothesized that in a co-culture experiment (2 cell lines at one time) of cancer cells which exclusively expresses one particular flower isoform, the cell lines which shows higher apoptotic fraction will behave as LOSE and the cell line which shows low apoptotic fractions will behave as UBI (kindly refer to the scheme of the research strategy (
The flower gene was knocked out of the genome of the MCF-7 and HCT cancer cell lines using zinc finger nucleases. To validate the successful knockout of Flower gene from these cell lines the expression of the Flower mRNA and Flower protein was observed using qPCR and western blotting respectively (
The 8 cell lines were co-transfected with CFP and GFP to generate 16 different cell lines 8 of MCF-7 origin and 8 of HCT origin (
| Number | Date | Country | Kind |
|---|---|---|---|
| 12155942.1 | Feb 2012 | EP | regional |
| 12156256.5 | Feb 2012 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2013/053163 | 2/18/2013 | WO | 00 |
